^
Association details:
| Biomarker: | BCR-ABL1 V299L |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exploiting temporal collateral sensitivity in tumor clonal evolution
Excerpt:
...BCR-ABL1 V299L expectedly conferred resistance to dasatinib and bosutinib, we observed strong and robust sensitization to crizotinib, foretinib, cabozantinib, and vandetanib...
DOI:
https://dx.doi.org/10.1016%2Fj.cell.2016.01.045
